| 000 | 01053 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250517052950.0 | ||
| 264 | 0 | _c20161025 | |
| 008 | 201610s 0 0 eng d | ||
| 022 | _a1476-5381 | ||
| 024 | 7 |
_a10.1111/bph.13331 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aO'Callaghan, G | |
| 245 | 0 | 0 |
_aProstaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? _h[electronic resource] |
| 260 |
_bBritish journal of pharmacology _cNov 2015 |
||
| 300 |
_a5239-50 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCarcinogenesis _xmetabolism |
| 650 | 0 | 4 |
_aDinoprostone _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xmetabolism |
| 650 | 0 | 4 |
_aReceptors, Prostaglandin E _xmetabolism |
| 650 | 0 | 4 | _aSignal Transduction |
| 700 | 1 | _aHouston, A | |
| 773 | 0 |
_tBritish journal of pharmacology _gvol. 172 _gno. 22 _gp. 5239-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bph.13331 _zAvailable from publisher's website |
| 999 |
_c25268559 _d25268559 |
||